Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DIVE INTO DIALYSIS: NxStage Aims To Transform Home Hemodialysis Into $2bn Market

This article was originally published in Clinica

Executive Summary

For the second part of Clinica’s three-part special series on the dialysis market, Reed Miller talked to the CEO of NxStage Medical, a Massachusetts-based company that markets the NxStage System One, which the firm touts as the only “truly portable” hemodialysis system FDA-cleared for home hemodialysis and home nocturnal hemodialysis. As the company is set to face competition for home hemodialysis customers from upstarts like Quanta, profiled in part 1 of this series, and giants like Fresenius Medical Care, the subject of part 3, NxStage is planning to use home hemodialysis as a “beachhead” to invade other, more lucrative markets

You may also be interested in...



Quanta Prepares For Launch Of SC+ Personal Dialysis Machine

The UK company recently finished a pilot trial of the SC+ personal dialysis system in France, as part of its plan to launch it in Europe by the end of 2018 and earn US FDA clearance in 2019.

Market Intel: Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth

End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.

Fresenius Homes In On NxStage

In a move to expand its dialysis empire into the growing home hemodialysis and critical care markets, Fresenius Medical Care has inked a $2bn deal to acquire NxStage Medical.

Topics

UsernamePublicRestriction

Register

MT103048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel